Indications
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
Composition
- Active substance
- brimonidine tartrate
- International name (INN)
- brimonidine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mirvaso
- Active substance
- brimonidine tartrate
- ATC code
- D11AX21
- Group
- Dermatologicals
- Therapeutic area
- Skin Diseases
- Marketing authorisation holder
- Galderma International
- Status
- Authorised
- EU authorisation